EPH receptor B1Genealiases: ELK · EPHT2 · Hek6 · NET
Q-omics provides the consensus-scored EPHB1 profile across patient tissues and cancer cell-line models. EPHB1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, EPHB1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, EPHB1 RNA expression shows 16,737 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, THCA, and TGCT as cancer lineages where EPHB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHB1 survival associations across molecular data types. EPHB1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHB1 RNA expression–survival associations across cancer types. High EPHB1 expression shows unfavorable associations in BLCA, UCEC and COAD, but favorable associations in LGG, ACC and CHOL. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for EPHB1 RNA expression.
This table summarizes EPHB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EPHB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHB1 shows lower tumor expression in THCA, LIHC, BRCA and KIRC and higher tumor expression in LUAD and LUSC. The THCA box plot shows higher EPHB1 RNA expression in normal versus tumor tissue (log2 FC = −2.402, t-test p < 0.001).
This table shows molecular features associated with EPHB1 in patient tissues and cancer cell lines. In patient samples, EPHB1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
